CLOSE

Specials

  • March
  • June
  • September
  • Bioanalytical Services
  • Life Science Analytics
  • Life Science Compliance
  • Bioanalytical Services APAC
  • APAC
  • Europe

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
APAC
  • Home
  • News
  • Contributors
  • Magazine
  • Conferences
  • Newsletter
  • About

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • Contributers

Recommended Insights

Managing Risk and Minimizing the...

Timothy Korwan, Director, New Product Development...

In Personalized Medicine Logistics,...

Scott Ohanesian, Senior VP Commercial Operations,...

Unlock the Power of Data

Jijo James, M.D., M.P.H., Chief Medical Officer,...

A Growing Reliance on Outsourcing Warrants...

Greg Aimi, Vice President, Team Manager, Supply...

AI Can Improve Patient Outcomes, but will...

Ryan Billings, MS, MBA, Executive Director, Digital...

Are Wearables and Sensors the Key to...

Marie McCarthy, Director, Product Innovation, ICON plc

What is Next After Serialisation?

Ulrike Kreysa, Senior Vice-President of Healthcare, GS1

The Challenge of Complex Biologics...

Ron Guido, VP, Regulatory Affairs, IRX Therapeutics

Managing Risk and Minimizing the...

Timothy Korwan, Director, New Product Development...

In Personalized Medicine Logistics,...

Scott Ohanesian, Senior VP Commercial Operations,...

Unlock the Power of Data

Jijo James, M.D., M.P.H., Chief Medical Officer,...

A Growing Reliance on Outsourcing Warrants...

Greg Aimi, Vice President, Team Manager, Supply...

AI Can Improve Patient Outcomes, but will...

Ryan Billings, MS, MBA, Executive Director, Digital...

Are Wearables and Sensors the Key to...

Marie McCarthy, Director, Product Innovation, ICON plc

What is Next After Serialisation?

Ulrike Kreysa, Senior Vice-President of Healthcare, GS1

The Challenge of Complex Biologics...

Ron Guido, VP, Regulatory Affairs, IRX Therapeutics

Leveraging Data to Improve Quality of Life

By A J Vallance-owen Mbe, Frcsed, Chief Medical Officer, Medicover Ab
Tweet

There is no question that technological advances, such as the development of big data and artificial intelligence, are already driving huge changes in practical health promotion, healthcare, and health-related research, and also in academic thinking.


In health promotion, there are now a number of innovative companies which promote good health in both the non-medical and medical spaces. Data (sometimes including genetic data) is collected from interested individuals and linked to significant evidence bases to enable advice on health priorities to be delivered online. As the database of anonymised personal data grows, now increasingly including post-advice feedback from those digital customers, so does the opportunity for artificial intelligence and machine learning, in itself now enhancing the original evidence base and driving constant improvement in the advice that can be given.


If the promised improvements to health are realised, this will benefit individuals and, if the numbers scale up (e.g. if employers get involved) then, over time, there could be an impact at population level; perhaps, at last, even a start to tackling the growing cost of chronic disease in healthcare systems.


In healthcare, collection of big data is becoming big business with huge opportunities, sometimes in areas of measurement that have been little used routinely because of cost and complexity. An example is the use of Patient Reported Outcome Measures (PROMs). The principal measure of clinical outcome routinely used has, historically, been the binary measure, mortality, i.e. dead or alive. Now, with digital technology, online systems, apps, etc., it is much easier for patients routinely to report the health benefits of their treatment using PROMs, which are properly validated survey tools.


In the UK, for example, the National PROMs Programme now has a massive database covering most of the hip and knee replacements done in the UK over the last few years.


This is big data which can be used to measure patient benefit beyond ‘alive’ (particularly quality of life), the value of the procedures to the healthcare system, to drive quality improvement and to get much needed early measures of outcome for new prostheses. My company, Medicover, is now starting to use some PROMs and the potential for driving improvements in surgical care and, increasingly, in the treatment of chronic disease is high. Another early benefit has been the growing evidence that, for many people with end-stage chronic disease or terminal cancer, quality of life is as important as survivability.


Another early benefit has been the growing evidence that, for many people with end-stage chronic disease or terminal cancer, quality of life is as important as survivability


The increasing collection and use of big data could also have an impact on health-related research. Randomised controlled trials have always been the gold standard for clinical research, but they are usually conducted on carefully selected populations and managed in tightly controlled settings. Many doctors in day-to-day clinical practice say that this is not evidence from the ‘real world’ which they inhabit; whereas data gathered from unselected populations in high volume through vehicles like PROMs (with appropriate case-mix adjustment), can provide real-world evidence which might be equally or more valuable to them as prescribers.


In summary, change is a constant factor. It is no surprise that pharmaceutical companies across the world have become so interested in real-world big data and I believe that effective health promotion can now become mainstream, dead or alive should no longer be the main measure of outcome, health benefit from treatment and resulting quality of life must be the new standard, and the use of real-world big data has to find a respectable place in academic research.


Weekly Brief

loading
Towards a New World Order
> <
  • Other 2021

    Top Vendors

    Current Issue
  • Other 2020

    Top Vendors

    Current Issue

Read Also

Proactive Strategies to Keep Container Fleet Intact

Bridget Grewal, Director of Packaging Continuous Improvement, Magna International
Proactive Strategies to Keep Container Fleet Intact

Improving Access to Quality and Critical Care through Telemedicine

Dr. Shireen Atabaki, M.D., MPH, Medical Director of Telehealth, Children’s National Health System
Improving Access to Quality and Critical Care through Telemedicine

The Evolving Role of Technology in Pharma

Aarti Shah, Ph.D., Senior Vice President, Chief Information and Digital Officer, Eli Lilly and Company
The Evolving Role of Technology in Pharma

Bioanalytics- A New Ray of Hope

Shan Chung, Ph.D. Associate, Director & Principal Scientist, Bio Analytical Sciences Genentech
Bioanalytics- A New Ray of Hope
The Imperative Need for BI and CDS Tech in Healthace

The Imperative Need for BI and CDS Tech in Healthace

Denise Juliano, Group Vice President of Life Sciences, Premier Inc.
Digitizing Pharmaceuticals

Digitizing Pharmaceuticals

By Ashok Upadhyay, IT Director, Otsuka Pharmaceutical Development & Commercialization, Inc. (U.S.)

Raising capital for early stage biotech start-ups

Dr. John Kurek, Inverstment Manager and Dr. Peter Devine, CEO, Uniseed
Raising capital for early stage biotech start-ups

Managing Risk and Minimizing the Complexity of Your Global Single-use Supply Chain

Timothy Korwan, Director, New Product Development and Commercialization, Avantor [NYSE:AVTR]
Managing Risk and Minimizing the Complexity of Your Global Single-use Supply Chain
Loading...

Copyright © 2021 Life Science Review . All rights reserved. |  Subscribe follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/cxoinsight/leveraging-data-to-improve-quality-of-life-nwid-56.html